Dr. Welslau on the Interim Results of the REFLECT Trial in DLBCL

Manfred Welslau, MD, discusses​ the interim results of the REFLECT trial in diffuse large B-cell lymphoma.

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses​ the interim results of the REFLECT trial in diffuse large B-cell lymphoma (DLBCL).

The REFLECT study is the first prospective post-approval trial evaluating the safety and efficacy of SDZ-RTX (Rixathon), a rituximab (Rituxan) biosimilar, in patients with untreated CD20-positive DLBCL.

As the field awaits the 24-month progression-free survival data, interim results from the study, presented during the 2020 ASCO Virtual Scientific Program, re-confirm the expected safety and efficacy profile of this biosimilar in patients with DLBCL.

Moreover, the overall response rate with SDZ-RTX was 88% with a complete response rate of 57% and partial response rate of 31%.

These real-world data do not suggest there are any significant differences between the biosimilar and the biologic, concludes Welslau.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD